Another New Drug in Trial

[Forseegood]

Dutch biotechnology firm OctoPlus said on Tuesday European safety and efficacy Phase IIa studies have shown an antiviral effect for its chronic hepatitis C drug Locteron.

"A statistically significant dose response was observed in the study," the company said in a statement, adding that the drug was tolerated at all doses.

The company, which has four other products in pre-clinical and clinical development, said approximately 90 percent of adverse events were rated as mild.

OctoPlus is co-developing Locteron with its partner Biolex Therapeutics, which plans to commence a European safety and efficacy Phase IIb trial of the drug in mid-2008.

With Locteron, OctoPlus is aiming to develop a treatment for patients with chronic hepatitis C, with fewer side effects and a more convenient dosing schedule compared with current therapies.

[GrandmaA]

That's very interesting. Gives the newbies hope.

[sunspot]

Thanks for posting about a new Hep-C drug in the pipeline. It gives one hope that this nasty virus can be eliminated in the near future.
I have to give a chuckle about “a more convenient dosing schedule”. That was on the bottom of the complaint list as far as a “cure” was concerned when I treated.

[Forseegood]

so good to see you! hope youre doing well....yeah, they seem to be throwing more firepower toward this dang little bug....so many new things happening....

[charm27]

Thanks alot for posting that, It is interesting......and eventually something has got to give. :}